PROGRAM

CSH Asia/ICMS Joint Conference on Tumor Microenvironment

Suzhou, China
November 13-17, 2012

TUESDAY, NOVEMBER 13, 2012

18:00 **GREETINGS**

18:15 **Isaac P. Witz,** Tel Aviv University, Tel Aviv, Israel
Introductory Remarks

18:30 **KEYNOTE LECTURE**

Introduced by **Isaac P. Witz**

Robert C. Gallo, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
Human tumor viruses—Old foes and new challenges P1

19:15 *Welcome Reception and Dinner*

WEDNESDAY, NOVEMBER 14, 2012

PLENARY SESSION 1

IMMUNITY IN THE TUMOR MICROENVIRONMENT

Chairperson: **W. H. Fridman,** Cordeliers Research Centre, Paris, France

8:30 **Xuetao Cao,** Chinese Academy of Medical Sciences, Beijing, China
Identification of new populations of immunosuppressive cells in tumor microenvironment **P2**

8:55 **Ron N. Apte**, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Interleukin-1 as a major cytokine detemining the balance between inflammation and immunity in the tumor microenvironment **P3**

9:20 **Michael R. Shurin**, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Environmental regulation of the tumor microenvironment **P4**

9:45 **Wolf H. Fridman**, Cordeliers Research Centre, Paris, France
Shaping the immune microenvironment—Soil or seed? **P5**

10:10 ***Coffee Break***

10:45 **KEYNOTE LECTURE**

Introduced by **Isaac P. Witz**

Carlo Croce, Ohio State University, Columbus, Ohio, USA
MicroRNAs can function as ligands for TLR and regulate the interactions between cancer cells and their microenviroment **P6**

PLENARY SESSION 2

REGULATORY EVENTS IN THE TUMOR MICROENVIRONMENT

Chairperson: **Chairperson: X. Cao,** Chinese Academy of Medical Sciences, Beijing, China

11:30 **Heike Allgayer**, University of Heidelberg, Mannheim, Germany
Defining key functions of microRNAs in several processes of the metastatic cascade **P7**

11:55 **Hidetoshi Tahara**, Graduate School of Biomedical Sciences Hiroshima University, Hiroshima, Japan
Senescence associated microRNAs and exosomes coordinately regulate cellular senescence and tumor microenvironment **P8**

12:20 ***Lunch***

PLENARY SESSION 2 *continued*

REGULATORY EVENTS IN THE TUMOR MICROENVIRONMENT

14:00 **Eitan Yefenof**, Hebrew University, Jerusalem, Israel
Steroid induced death of hemopoietic cancer cells—An interplay between protein kinases and micro RNAs **P9**

14:25 **Baocun Sun**, Tianjin Medical University, Tianjin, China
Study on vasculogenic mimicry and its molecular mechanism **P10**

14:50 **Yongzhang Luo**, Tsinghua University, Beijing, China
The CXCL12 (SDF-1α)/CXCR4 axis regulates both tumor angiogenesis and lymphangiogenesis **P11**

15:15 **Theresa Guise**, Indiana University, Indianapolis, Indiana, USA
Muscle dysfunction associated with bone metastases—Role of ryanodine receptor remodeling **P12**

15:40 **KEYNOTE LECTURE**

Introduced by: **Isaac P. Witz**

Peter H. Krammer, German Cancer Research Center (DKFZ), Heidelberg, Germany
Regulation of the immune response by Annexin I **P13**

16:25 **POSTER VIEWING and CHINESE TEA & BEER TASTING**

Full list of posters can be found on page xvii of the program

18:00 ***Dinner***

PLENARY SESSION 3

INFLAMMATION IN THE TUMOR MICROENVIRONMENT

Chairperson: **L. Li,** Nankai University School of Pharmaceutical Science, Tianjin, China

19:30 **Luyuan Li**, Nankai University, Tianjin, China
TNFSF15 modulates angiogenesis and inflammation **P14**

19:55 **Adit Ben-Baruch**, Tel Aviv University, Tel Aviv, Israel
Regulation of pro-angiogenic switch and cell-remodeling by the inflammatory microenvironment in breast cancer **P15**

20:20 **Alberto Mantovani**, Istituto Clinico Humanitas IRCCS, Milan, Italy
The yin-yang of tumor associated macrophages and cancer-related inflammation **P16**

20:45 **Neta Erez**, Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel
Pro-inflammatory signaling by cancer-associated fibroblasts co-evolves along defined tumor stages of mammary carcinogenesis **P17**

21:10 **Subhra K. Biswas**, A*STAR, Singapore
A protumoral role for myelomonocytic cells in human cancer progression-A molecular insight **P18**

THURSDAY, NOVEMBER 15, 2012

8:30-13:00 **PARALLEL SYMPOSIUM SESSIONS 1-3**

14:00 *Visit to Old Suzhou*

SYMPOSIUM 1

REGULATORY NETWORKS IN THE TUMOR MICROENVIRONMENT

Chairpersons: **D. Hoon,** John Wayne Cancer Institute, Santa Monica, California, USA
A. Thomas-Tikhonenko, University of Pennsylvania School of Medicine, Philadelphia, USA

8:30 **Dave S. Hoon**, John Wayne Cancer Institute, Santa Monica, California, USA
B7-H3 cell surface molecule associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma **S1-1**

8:50 **Andrei Thomas-Tikhonenko**, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Pro-angiogenic microRNAs in colorectal cancer—Lessons from mouse models and cancer genomics **S1-2**

9:10 **Reuven Reich**, Institute of Drug Research, Jerusalem, Israel
MicroRNA-mediated regulation of ovarian carcinoma—Role of exosomes **S1-3**

9:25 **Yaw-Chyn Lim**, National University of Singapore, Singapore
Breast cancer cells modulate the tissue microenvironment of distant sites to facilitate metastasis **S1-4**

9:40 **Shelly Tartakover Matalon**, Tel Aviv University, Tel Aviv, Israel; Meir Medical Center, Kfar Saba, Israel
Dr. Jekyll and Mr. Hyde—The placenta's dual effect on the metastatic potential of breast cancer cells **S1-5**

9:55 **Eli Breuer**, Hebrew University, Jerusalem, Israel
Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2 **S1-6**

10:10 **Ying Wei**, University of California San Francisco, San Francisco, California, USA
Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia **S1-7**

10:25 *Coffee Break*

11:00 **Rachel Bar-Shavit**, Hadassah-Hebrew University Hospital, Jerusalem, Israel
Emerging tasks of $PAR_{1\&2}$ in breast cancer—Molecular mechanism and translational outcome **S1-8**

11:15 **Linda J. Metheny-Barlow**, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
Activation of a BDNF-p75NTR axis in breast cancer brain metastatic cells by the microenvironment **S1-9**

11:30 **Abdelilah Aboussekhra**, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
Role of p16INK4A and caffeine in suppressing the expression/secretion of IL-6 and the pro-carcinogenic effects of breast cancer-associated fibroblasts **S1-10**

11:45 **Ben-Zion Katz**, Tel-Aviv Medical Center, Tel-Aviv, Israel
Divergence in CD19-mediated signaling unfolds intra-clonal diversity in chronic lymphocytic leukemia which correlates with disease progression **S1-11**

12:00 **Xiyun Yan**, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
The role of CD146 in tumor cell migration and tumor angiogenesis **S1-12**

12:15 **Rami Aqeilan**, Hebrew University, Jerusalem, Israel
A pleiotropically tumor suppressor WWOX, inhibits breast cancer metastasis **S1-13**

SYMPOSIUM 2

FUNCTIONAL GENETICS OF FIBROBLASTS IN THE TUMOR MICROENVIRONMENT

Chairperson: A. Ostman, Karolinska Institutet, Stockholm, Sweden

8:30 **Arne Östman**, Karolinska Institutet, Stockholm, Sweden
Impact of PDGFR-positive CAFs on prognosis, drug response and metastasis **S2-1**

8:50 **Zhihai Qin**, Institute of Biophysics, CAS, Beijing, China
Microtubule modification in stromal fibroblasts accelerates inflammation and tumor progression **S2-2**

9:10 **Donghui Zou**, University of Otago, Dunedin, New Zealand
Gene expression differences between colorectal cancer derived CAFs and colonic fibroblasts illustrate CAF biology **S2-3**

9:25 **Catherine Muller**, IPBS CNRS UMR 5089, Toulouse, France
Adipocyte-derived fibroblasts (ADFs), a newly identified stromal cell population, promote tumor progression and contribute to desmoplastic reaction in breast cancer **S2-4**

9:40 **Cecilia S. Leung**, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer associated fibroblast derived MFAP5 regulates ovarian cancer cell motility and invasion potential through calcium dependent CREB/TNNC1 signaling pathways **S2-5**

9:55 **Tao Shan**, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China
Caveolin-1, as a novel biomarker of lethal tumor microenvironment, is inhibited via autophagy in pancreatic cancer associated fibroblasts cells **S2-6**

SYMPOSIUM 3

CYTOKINE AND CHEMOKIINE NETWORKS IN THE TUMOR MICROENVIRONMENT

Chairperson: L. Borsig, University of Zurich, Switzerland

10:10 **Lubor Borsig**, University of Zürich, Zurich, Switzerland
Colon carcinoma extravasation is induced by CCL2-induced signaling through endothelial CCR2 that is mediated through the JAK2-Stat5 and p38MAPK pathway **S3-1**

10:30 ***Coffee Break***

11:00 **Joseph Kwong**, The Chinese University of Hong Kong, Shatin, Hong Kong
Cancer cell-derived lymphotoxin mediates reciprocal tumor-stromal interactions in ovarian cancer by inducing fibroblast-secreting CXCL11 **S3-2**

11:15 **Bo Zhu**, Xinqiao Hospital Institute of Cancer, Chongqing, China
Cancer stem cells enhance invasion of cancer cells via CCL-5-mediated epithelial-mesenchymal transition **S3-3**

11:30 **Etta Livneh**, Ben Gurion University of the Negev, Beer Sheva, Israel
PKC and its polymorphism enhance secretion of the pro-inflamatory cytokine IL-6 and are involved in establishing cellular senescence **S3-4**

11:45 **Elena Voronov**, Ben Gurion University of the Negev, Beer Sheva, Israel
The effects of IL-1 on colorectal cancer development **S3-5**

12:00 **Li Yang**, National Cancer Institute, Bethesda, Maryland, USA
Tumor microenvironment, the answer for the puzzling dual function of TGFβ **S3-6**

12:15 **Marcelo Ehrlich**, Tel Aviv University, Tel Aviv, Israel
Transport and signaling of the receptors for transforming growth factor-β (TGF-β)—Regulation by molecular motifs, cellular factors and the cell cycle **S3-7**

12:30 **Akira Saito**, University of Tokyo, Tokyo, Japan
An integrated expression profiling reveals target genes of TGF-β and TNF-α possibly mediated by microRNAs in lung cancer cells S3-8

13:00 ***Lunch***

14:00 ***Visit to Old City of Suzhou and free evening***

FRIDAY, NOVEMBER 16, 2012

PLENARY SESSION 4

REGULATORY EVENTS IN THE TUMOR MICROENVIRONMENT III

Chairperson: A. Raz, Wayne State University, Detroit, Michigan, USA

8:30 **Takahiro Ochiya**, National Cancer Center, Tokyo, Japan
Exosome as a novel regulator of tumor-microenvironment **P19**

8:55 **Menashe Bar-Eli**, UT MD Anderson Cancer Center, Houston, Texas, USA
Driving genes in melanoma metastasis—The role of the tumor microenvironment **P20**

9:20 **Bernd Groner**, Georg Speyer Haus, Frankfurt am Main, Germany
Reciprocal interactions between stromal and epithelial cells regulate the ductal outgrowth during glandular development and the invasive potential of metastasizing mammary tumor cells **P21**

9:45 **Avraham Raz**, Wayne State University, School of Medicine, Detroit, Michigan, USA
On the role of autocrine motility factor-a tumor secreted cytokine in cancer progression and metastasis **P22**

10:10 ***Coffee Break***

10:45 **Raghu Kalluri**, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Fibrosis and cancer progression **P23**

11:10 **Yu-quan Wei**, The State Key Lab of Biotherapy, West China Hospital, Chengdu, China
Proteomics analysis of tumor microenvironment—implications of metabolic and oxidative stresses in tumorigenesis **P24**

11:35 **Senthil K. Muthuswamy**, University of Toronto, Toronto, Canada; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA
Loss of cell polarity and metastasis—Synergy with oncogenes or the microenvironment **P25**

12:00 ***Lunch and Poster Viewing***

13:45 **POSTER SESSION**

Oral presentation of selected posters and awarding of poster prizes

Full list of posters begins on page xvii of the program

PLENARY SESSION 5

TARGETING THE TUMOR MICROENVIRONMENT

Chairperson: **F. Balkwill,** Queen Mary University of London,United Kingdom

15:30 **Frances R. Balkwill**, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Targeting the peritoneal tumor microenvironment of high grade serous ovarian cancer **P26**

15:55 **Yutaka Kawakami**, Keio University School of Medicine, Tokyo, Japan
Mechanisms for cancer induced immunosuppression in tumor associated microenvironments and their reversal by targeting altered signaling pathways in cancer cells and immune cells **P27**

16:20 **Robert S. Kerbel**, Sunnybrook Research Institute, Toronto, Canada
Differential therapeutic outcomes when treating primary orthotopic tumors versus visceral metastases **P28**

16:45 **Yona Keisari**, Tel Aviv University, Tel Aviv, Israel
Ablation of solid tumors by intratumoral pulsed electric currents or alpha radiation activates anti-tumor immune responses that can target residual disease **P29**

17:10 **Jacques Pouyssegur**, Institute for Research on Cancer and Aging (IRCAN), University of Nice, CNRS, INSERM, Nice, France
Genetic disruption of CD147/ Basigin, a subunit of lactate-H^+/ symporters (MCTs), sensitizes glycolytic tumour cells to phenformin **P30**

17:35 **SPECIAL SESSION**

Submission to High Impact Journals

Discussion Leader: Nicola McCarthy, Chief Editor, Nature Reviews Cancer

18:00 ***Cocktails and Conference Dinner***

SATURDAY, NOVEMBER 17, 2012

8:30-13:00 **PARALLEL SYMPOSIUM SESSIONS 4-5**

SYMPOSIUM 4

INFLAMMATION AND IMMUNITY IN THE TUMOR MICROENVIRONMENT

Chairpersons: **J.-P. Abastado,** A-STAR, Singapore
A. Porgador, Ben Gurion University of the Negev, Beer Sheva, Israel

8:30 **Jean-Pierre Abastado**, A-STAR, Singapore
Chemokines shape the immune tumor microenvironment **S4-1**

8:50 **Angel Porgador**, Ben-Gurion University of the Negev, Beer Sheva, Israel
The function of NCRs in health and cancer—Emphasis on isoforms **S4-2**

9:10 **Limin Zheng**, Sun Yat-sen University, Guangzhou, China
Dynamic regulating the immune responses by different anatomic areas in human tumors **S4-3**

9:30 **Reuven Stein**, Tel Aviv University, Tel Aviv, Israel
CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages **S4-4**

9:50 **Viktor Umansky**, German Cancer Research Center and University Hospital Mannheim, Heidelberg, Germany
Overcoming immunosuppression in melanoma microenvironment induced by chronic inflammation **S4-5**

10:10 ***Coffee Break***

10:30 **Diane Damotte**, Institut National de la Santé et de la Recherche Médicale (INSERM), U872, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie, Paris, France; Université Paris Descartes, Paris, France
Composition, organization and clinical impact of the adaptive and innate immune microenvironments in lung metastases from colorectal and renal cell carcinoma **S4-6**

10:45 **Alexandre Corthay**, University of Oslo, Oslo, Norway
Tumor-specific Th2 cells collaborate with M2 macrophages to eradicate cancer **S4-7**

11:00 **Michal Baniyash**, Hebrew University Hadassah Medical School, Jerusalem, Israel
Chronic inflammation-induced immunosuppression—Underlying mechanisms and clinical implication in cancer **S4-8**

11:15 **Cremer Isabelle**, UMRS 872 INSERM, Team 13, Paris, France
TLR7 in non-small cell lung carcinoma (NSCLC) patients—A double-edged sword **S4-9**

11:30 **Julia Kzhyshkowska**, University of Heidelberg, Mannheim, Germany
Stabilin-1 is expressed on tumor-associated macrophages on early stages in breast cancer and supports tumor growth in animal breast cancer model by clearance of SPARC **S4-10**

11:45 **Arthur A. Hurwitz**, National Cancer Institute, Frederick, Maryland, USA
Tumor-associated mast cells suppress anti-tumor immunity via IL-13 and TGF-β **S4-11**

SYMPOSIUM 5

TARGETING THE TUMOR AND THE TUMOR MICROENVIRONMENT

Chairpersons: **R. Ge,** National University of Singapore, Singapore
T. ten Hagen, Erasmus Medical Center, Rotterdam, the Netherlands

8:30 **Ruowen Ge**, National University of Singapore, Singapore
Novel functions of a proteoglycanase— ADAMTS5 (aggrecanase-2) functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity **S5-1**

8:50 **Shelly Maman**, Tel-Aviv University, Tel-Aviv, Israel; The Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland
Micrometastasis regulation by the lung microenvironment in neuroblastoma **S5-2**

9:05 **Timo LM. ten Hagen**, Erasmus MC, Rotterdam, the Netherlands
Utilization and manipulation of the tumor microenvironment to improve drug delivery to solid tumors **S5-3**

9:25 **Ingrid Herr**, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany
Selection of established and primary models of pancreatic cancer stem cells and therapeutic targeting **S5-4**

9:45 **Liat Drucker**, Tel Aviv University, Tel Aviv, Israel; Meir Medical Center, Kfar Saba, Israel
Translation initiation as a novel platform for targeting myeloma-microenvironment interactions **S5-5**

10:00 ***Coffee Break***

10:30 **Albrecht Reichle**, University Regensburg, Regensburg, Germany
A phase II study of Imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan—Combined anti-osteoplastic, anti-inflammatory, immunomodulatory and angiostatic treatment in patients with CRPC **S5-6**

10:45 **Zhengqiang Yuan**, University College London, London, United Kingdom
Reduction of lung metastasis by engineered mesenchymal stem cells expressing TRAIL **S5-7**

11:00 **Andrei V. Bakin**, Roswell Park Cancer Institute, Buffalo, New York, USA
Targeting TAK1 in cancer progression and metastasis **S5-8**

11:15 **Hélène Haegel**, Transgene SA, Illkirch-Graffenstaden, France
An anti-CD115 monoclonal antibody targeting both tumor cells and myeloid cells involved in cancer progression—Inhibition of osteoclast and M2-polarized macrophages **S5-9**

11:30 **Michael Grusch**, Medical University of Vienna, Vienna, Austria
Deregulation of the FGF/FGF-receptor axis during melanoma progression—Opportunities for simultaneous targeting of tumor cells and the microenvironment **S5-10**

11:45 **Martina Seiffert**, German Cancer Research Center, Heidelberg, Germany
The immunomodulatory drug lenalidomide reduces survival of chronic lymphocytic leukemia cells by targeting the inflammatory microenvironment **S5-11**

12:00 **Shihui Liu**, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
Treating solid tumors with tumor-associated protease-activated anthrax toxins **S5-12**

POSTERS

Posters will be displayed for the duration of the conference

Jennifer H.E. Baker, University of British Columbia, Vancouver, Canada; BC Cancer Research Centre, Vancouver, Canada

Investigating the highly heterogeneous distribution of trastuzumab in Her2-overexpressing cancer xenografts using DCE-MRI and histology **Pos1**

Xingfeng Bao, Eisai Inc, Andover, Massachusetts, USA

Antagonism of PGE_2 receptor type-4 induces an effective anti-tumor immune response by promoting APC differentiation **Pos2**

Shijie Cai, University of Oxford, Oxford, United Kingdom; Huaqiao University, Quanzhou, China

Stromal fibroblast GTP cyclohydrolase expression facilitates tumor angiogenesis and progression **Pos3**

David W. Chan, The University of Hong Kong, Pokfulam, Hong Kong

The AMP-activated protein kinase gamma-2 (AMPK-γ2) subunit acts as a modifier of AMPK activity in ovarian cancer cells **Pos4**

Mo Chen, National University of Singapore, Singapore

The novel angiogenesis inhibitor Isthmin inhibits angiogenesis through GRP78-mediated internalization **Pos5**

Yu-Che Cheng, Academia Sinica, Taipei, Taiwan

BTG3 suppresses tumorigenesis and metastasis by antagonizing the AKT–GSK3β–β-catenin signaling pathway **Pos6**

Valerie SP. Chew, Singapore Immunology Network, Singapore

Toll-like receptor 3-expressing tumor parenchyma and infiltrating natural killer cells promote tumor control in hepatocellular carcinoma **Pos7**

Yoon Pyo Choi, Yonsei University College of Medicine, Seoul, South Korea

Synergistic effect for the combination of ILK and β4 integrin as an anticancer target in ovarian cancer **Pos8**

Hila Confino, Sackler Faculty of Medicine, Tel - Aviv, Israel

Induction of anti-tumor immunity against experimental metastatic tumors following tumor ablation by intratumoral RA-224 loaded wires **Pos9**

Matthew T. Drake, Mayo Clinic, Rochester, Minnesota, USA

Overexpression of CCL3/MIP-1α induces diffuse bone loss in a novel murine model of human multiple myeloma **Pos10**

Min Fang, Zhongnan Hospital of Wuhan University, Wuhan, China

Co-evolution of tumor microenvironment revealed by QDs-based multiplexed imaging of hepatocellular carcinoma **Pos11**

Sivan Izraely, Tel Aviv University, Tel Aviv, Israel

Specificity and functions of molecules associated with melanoma brain metastasis **Pos24**

Tianxia Jiang, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

CD146 is a co-receptor for VEGFR-2 in tumor angiogenesis **Pos25**

Jing Jiao, University of California Los Angeles, Los Angeles, California, USA

Cell type specific role of COX2 on skin cancer development **Pos26**

Ki-Rim Kim, Yonsei University College of Dentistry, Seoul, South Korea

15-deoxy-$\Delta^{12,14}$-prostaglandin J_2 inhibits osteolytic bone metastasis of breast cancer cells **Pos27**

Sara Lamorte, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; University of Torino, Torino, Italy

Multiple myeloma perivascular niche perturbs bone marrow function—Role of delta like ligand 4 **Pos28**

Nongnit Laytragoon-Lewin, Ryhov Hospital Clinical Microbiology, Jönköping, Sweden

Prognostic biomarkers, plasma CRP and TNFa on survival of head and neck squamous cell carcinoma (HNSCC) patients **Pos29**

Eun-Jung Lee, Yonsei University Health System, Seoul, South Korea

Down-regulation of IL-12 though IL-6 production increased treatment failure after radiotherapy of hepatocellular carcinoma **Pos30**

Qun-Ying Lei, Fudan University,Shanghai Medical College, Shanghai, China; Fudan University, Institutes of Biomedical Sciences, Shanghai, China

Acetylation negatively regulates lactate dehydrogenase A and is downregulated in pancreatic cancer **Pos31**

Kristina Levan, Sahlgrenska Cancer Center, Gothenburg, Sweden

Characterization of genes involved in epithelial mesenchymal transition in SKOV-3 and OVCAR-3 cells **Pos32**

Bing Li, University of Minnesota, Austin, Minnesota, USA

Adipose fatty acid binding protein accelerates cancer progression **Pos33**

Cong Li, Fudan University, Shanghai, China

Imaging intratumoral acidosis by using a pH-activatable near-infrared fluorescence probe in vivo **Pos34**

Dan Liu, Vanderbilt University, Nashville, Tennessee, USA; Yale University, New Haven, Connecticut, USA

Loss of LZAP inactivates p53 in head and neck cancer and regulates sensitivity of cells to DNA damage in the p53-dependent manner **Pos35**

Li Liu, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

The regulatory pathways and controlling mechanisms involved in NOK oncogene mediated glucose metabolism **Pos36**

Li Liu, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany

Triptolide from TCM abolishes NF-□B-signaling, EMT and stem-like features in an hypoxic microenvironment of pancreatic cancer **Pos37**

Su Hao Lo, University of California - Davis, Sacramento, California, USA

Cten functions as a novel quantity controller of epidermal growth factor receptor **Pos38**

Noor A. Lokman, University of Adelaide, Adelaide, Australia

Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour **Pos39**

Ida Lundberg, Umeå University, Umeå, Sweden

Different subgroups of colorectal cancer and adjacent fibroblasts **Pos40**

Samuel Lundin, University of Gothenburg, Gothenburg, Sweden

Cancer associated fibroblast (CAF) footprints in the transcriptional profiles of gastric tumor- and non-tumor tissue **Pos41**

Yunus A. Luqmani, Kuwait University, Safat, Kuwait

Factors influencing proliferation and invasion of endocrine resistant breast cancer cells **Pos42**

Tsipi Meshel, Tel-Aviv University, Tel-Aviv, Israel

Mechanisms regulating the secretion of the inflammatory chemokine CCL2 in breast tumor cells **Pos43**

Tsipi Meshel, Tel-Aviv University, Tel-Aviv, Israel

The role of PhoX2B in micro and macro metastases of neuroblastoma **Pos44**

Adriana Michielsen, Institute of Molecular Medicine, St. James's Hospital, Trinity College Dublin, Dublin, Republic of Ireland

The tissue microenvironment in Barrett's Oesophagus induces dendritic cell maturation **Pos45**

Neda Moazzezy, Pasteur Institute of Iran, Tehran, Iran

Biomarker expression in blood and tissue of breast cancer patients **Pos46**

Elin Möllerström, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

Subpopulations of cells within human astrocytomas determined by single cell gene expression profiling **Pos47**

Jennifer M. Munson, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland

Lymphatic endothelial cell-induced stromal stiffening caused by activation of fibroblasts in the tumor microenvironment **Pos48**

Daotai Nie, Southern Illinois University School of Medicine, Springfield, Illinois, USA

Microenvironmental regulation of tumor metastasis through thromboxane A2-receptor signalling axis **Pos49**

Se Young Park, Yonsei University College of Dentistry, Seoul, South Korea

Inhibitory effect of betulinic acid on breast cancer-associated bone diseases **Pos50**

E Pomianowska, University of Oslo, Oslo, Norway

Role of cyclooxygenase-2 and prostaglandin E2 in stellate cells from pancreatic cancer **Pos51**

Yael Raz, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Characterization of cancer associated fibroblasts in mammary gland carcinoma **Pos52**

Albrecht Reichle, University Regensburg, Regensburg, Germany

Biomodulatory therapy approaches—Renal clear cell carcinoma **Pos53**

Albrecht Reichle, University Regensburg, Regensburg, Germany

Formal-pragmatic communication theory as prerequisite for an evolution-adjusted tumor pathophysiology **Pos54**

Albrecht Reichle, University Regensburg, Regensburg, Germany

Practical relevance of an evolution theory for understanding tumor development and for specifying tumor therapy **Pos55**

Thomas Reinheckel, Albert-Ludwigs-University, Freiburg, Germany

Cysteine cathepsins as tumor-promoting extracellular proteases in the microenvironment of murine breast cancer **Pos56**

Carmela Ricciardelli, University of Adelaide, Adelaide, Australia

Carboplatin-induced hyaluronan production—A chemoresistance mechanism in ovarian cancer **Pos57**

Orit Sagi-Assif, Tel-Aviv University, Tel-Aviv, Israel

The metastatic microenvironment—Survival of melanoma cells in the brain is regulated by interactions with the brain microenvironment **Pos58**

Francis H.W. Shand, University of Tokyo, Tokyo, Japan; CREST, Tokyo, Japan; University of Melbourne, Parkville, Australia

The contribution of spleen-pool myeloid cells to tumor infiltration **Pos59**

Yoray Sharon, Tel-Aviv university, Tel-Aviv, Israel

Mammary fibroblasts are activated to become pro-inflammatory by breast tumor cells **Pos60**

Elin Sjoberg, Karolinska Institute, Stockholm, Sweden

Towards identification of a receptor for the orphan chemokine CXCL14 **Pos61**

Alex Soltermann, University Hospital Zurich, Zurich, Switzerland

Epithelial-mesenchymal transition at the tumor-stroma interface of non-small cell lung carcinoma **Pos62**

Rakesh Srivastava, University of Kansas Medical Center, Kansas City, USA

Clinical potential of NPV-LDE-225 (Erismodegib) for the treatment of brain cancer by targeting glioblastoma initiating cells **Pos63**

Olga Tatti, Helsinki University, Research Program Unit, Helsinki, Finland

MT3-MMP regulates melanoma growth and vascular intravasation **Pos64**

Alimatou M. Tchafa, Drexel University, Philadelphia, Pennsylvania, USA

Combined role of interstitial fluid flow and ErbB2 expression on breast cancer progression **Pos65**

Timo LM. ten Hagen, Erasmus MC, Rotterdam, the Netherlands

Melanoma and endothelial cell communication affect tumor aggressiveness **Pos66**

Chia-Lung Tsai, Chang-Gung Memorial Hospital, Kwei-Shan, Taoyuan, Taiwan

Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells **Pos67**

Nithya Rao Velliyuir Nott, National University of Singapore, Singapore

ADAMTS4—A new role in angiogenesis and cancer **Pos68**

Juan-Jose Ventura, University of Cambridge, Cambridge, United Kingdom

Unraveled a paracrine network underlying the potential of human lung stem cells to establish their own niche **Pos69**

Bo Wang, State Key Laboratory of Oncology in South China, Guangzhou, China

Mast cells in muscularis propria producing interleukin 17 predicts favorable prognosis in esophageal squamous cell carcinoma **Pos70**

Yuan Yuan Wang, IPBS CNRS UMR 5089, Toulouse, France; INSERM U1048, Toulouse, France; The First Affiliated Hospital of Chongqing Medical University, ChongQing, China

Tumor-surrounding adipocytes provide energetic support to breast cancer cells, through fatty acid β-oxidation, to promote tumor progression **Pos71**